degarelix
degarelix: 15 clinical trials tracked.
degarelix evidence translation
What we can confirm
15 tracked trials
What it means
What to watch
Prepared research question
What is verified about degarelix, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 4 study sponsors
Clinical Trials (15)showing 10 most recent
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate Cancer
Primary endpoint: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer
Primary endpoint: Modified radiographic progression-free survival (mrPFS) (Groups A & B)
ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer
Primary endpoint: Change in Ki-67
A Phase 1/2 Study of Darolutamide and Abemaciclib in High-Risk Prostate Cancer
Primary endpoint: Phase 1 - Maximum Tolerated Dose (MTD)
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
Primary endpoint: Body Mass Index (BMI)
Phase I/II Trial of Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
Primary endpoint: Pathological Complete Response Rate (pCR)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Primary endpoint: Distant metastasis (DM) (De-intensification study)
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Radiographic progression-free survival (rPFS)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Primary endpoint: Metastasis-free survival (MFS)
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Primary endpoint: Progression-free survival (PFS)